01. Gene therapy Boulikas.pdf - Gene therapy & Molecular Biology

Hanna AK, Fox JC, Neschis DG, Safford SD, Swain JL, Golden
MA (1997) Antisense basic fibroblast growth factor gene
transfer reduces neointimal thickening after arterial injury. J
Vasc Surg 25, 320-325.
Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets
R, Lu Y, Canessa C, Iwasaki T, Rossier B, Lifton RP (1995)
Hypertension caused by a truncated epithelial sodium
channel γ subunit: genetic heterogeneity of Liddle syndrome.
Nat Genet 11, 76-82.
Harms JS, Splitter GA (1995) Intergeron-g inhibits transgene
expression driven by SV40 or CMV promoters but augments
expression driven by the mammalian MHC I promoter. Hum
Gene Ther 6, 1291-1297.
Harrell RL, Rajanayagam S, Doanes AM, Guzman RJ,
Hirschowitz EA, Crystal RG, Epstein SE, Finkel T (1997)
Inhibition of vascular smooth muscle cell proliferation and
neointimal accumulation by adenovirus-mediated gene
transfer of cytosine deaminase. Circulation 96, 621-627.
Hart Sl (1994) Cell binding and internalization by filamentous
phage displaying a cyclic Arg-Gly-Asp-containing peptide. J
Biol Chem 269, 12468-12474.
Hay JG, McElvaney NG, Herena J, Crystal RG (1995)
Modification of nasal epithelial potential differences of
individuals with cystic fibrosis consequent to local
administration of a normal CFTR cDNA adenovirus gene
transfer vector. Hum Gene Ther 6, 1487-1496.
Hay, R.T. (1985) Origin of adenovirus DNA replication. Role of
the Nuclear Factor I binding site in vivo. J. Mol. Biol. 186,
129-136.
Hayday, A.,C., Gillies, S.D., Saito, H., Wood, C., Wiman, K.,
Hayward, W.S. and Tonegawa, S. (1984) Activation of a
translocated human c-myc gene by an enhancer in the
immunoglobulin heavy-chain locus. Nature 307, 334-340.
Hayward WS, Neel BG, Astrin SM (1981) Activation of a
cellular onc gene by promoter insertion in ALV-induced
lymphoid leukosis. Nature 290, 475-480.
Hazinski TA, Ladd PA, DeMatteo CA (1991) Localization and
induced expression of fusion genes in the rat lung. Am J
Respir Cell Mol Biol 4, 206-209.
Heise C, Sampson-Johannes A, Williams A, McCormick F, Von
Hoff DD, Kirn DH (1997) ONYX-015, an E1B geneattenuated
adenovirus, causes tumor-specific cytolysis and
antitumoral efficacy that can be augmented by standard
chemotherapeutic agents. Nat Med 3, 639-645.
Helin K, Lees JA, Vidal M, Dyson N, Harlow E, Fattaey A
(1992) A cDNA encoding a pRB-binding protein with
properties of the transcription factor E2F. Cell 70, 337-350.
Hermeking H and Eick D (1994) Mediation of c-Myc-induced
apoptosis by p53. Science 265, 2091-2093.
Hermonat PL, and Muzyczka N (1984) Use of adeno-associated
virus as a mammalian DNA cloning vector: Transduction of
neomycin resistance into mammalian tissue culture cells.
Proc Natl Acad Sci USA 81, 6466-6470.
Hermonat PL, Quirk JG, Bishop BM, Han L (1997) The
packaging capacity of adeno-associated virus (AAV) and the
potential for wild-type-plus AAV gene therapy vectors.
FEBS Lett 407, 78-84.
Boulikas: An overview on gene therapy
142
Herrmann JL, Beham AW, Sarkiss M, Chiao PJ, Rands MT,
Bruckheimer EM, Brisbay S, McDonnell TJ (1997) Bcl-2
suppresses apoptosis resulting from disruption of the NF-κB
survival pathway. Exp Cell Res 237, 101-109.
Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff
R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH,
Kobayashi AL, et al (1987) Treatment of adenosine
deaminase deficiency with polyethylene glycol-modified
adenosine deaminase. N Engl J Med 316, 589-596.
Herz J and Gerard RD (1993) Adenovirus-mediated transfer of
low density lipoprotein receptor gene acutely accelerates
cholesterol clearance in normal mice. Proc Natl Acad Sci
USA 90, 2812-2816.
Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher
KJ, High KA (1997) Stable gene transfer and expression of
human blood coagulation factor IX after intramuscular
injection of recombinant adeno-associated virus. Proc Natl
Acad Sci USA 94, 5804-5809.
Hiebert SW, Packham G, Strom DK, Haffner R, Oren M,
Zambetti G, and Cleveland JL (1995) E2F-1:DP-1 induces
p53 and overrides survival factors to trigger apoptosis. Mol
Cell Biol 15, 6864-6874.
Hirschhorn R, Roegner-Maniscalco V, Kuritsky L, Rosen FS
(1981) Bone marrow transplantation only partially restores
purine metabolites to normal in adenosine deaminasedeficient
patients. J Clin Invest 68, 1387-1393.
Hoeben RC (1998) Gene therapy for haemophilia. Gene Ther
Mol Biol 1, 293-300.
Hofland HEJ, Shephard L, Sullivan SM (1996) Formation of
stable cationic lipid/DNA complexes for gene transfer. Proc
Natl Acad Sci USA 93, 7305-7309.
Hofmann C, Lehnert W, and Strauss M (1997) The baculovirus
vector system for gene delivery into hepatocytes. Gene Ther
Mol Biol 1,
Hollenberg NK (1996) Genes, hypertension, and intermediate
phenotypes. Curr Opin Cardiol 11, 457-463.
Hollstein M, Sidransky D ,Vogelstein B, Harris CC (1991) p53
mutations in human cancers. Science 253, 49-53.
Holt JT, Arteaga CB, Robertson D, Moses HL (1996) Gene
therapy for the treatment of metastatic breast cancer by in
vivo transduction with breast-targeted retroviral vector
expressing antisense c-fos RNA. Hum Gene Ther 7, 1367-
1380.
Horellou P, Mallet J (1997) Gene therapy for Parkinson's
disease. Mol Neurobiol 15, 241-256.
Horn NA, Meedi JA, Budahazi G, Marquet M (1995) Cancer
gene therapy using plasmid DNA: Purification of DNA for
human clinical trials. Hum Gene Ther 6, 565-573.
Horowitz JM, Yandell DW, Park S-H, Canning S, Whyte P,
Buchkovich K, Harlow E, Weinberg RA, Dryja TP (1989)
Point mutational inactivation of the retinoblastoma
antioncogene. Science 243, 937-940.
Hu E, Kim JB, Sarraf P, and Spiegelman BM (1996) Inhibition
in adipogenesis through MAP kinase-mediated
phosphoryl;ation of PPARγ. Science 274, 2100-2103.
Huang H-JS, Yee J-K, Shew J-Y, Chen P-L, Bookstein R,
Friedmann T, Lee EYHP, Lee W-H (1988) Suppression of